NEWS & MEDIA
October 18, 2022
DRS. ROGER B. COHEN, LEE M. ELLIS AND JOHN L. MARSHALL JOIN ACTUATE THERAPEUTICS’ SCIENTIFIC ADVISORY BOARD
October 28, 2021
ACTUATE THERAPEUTICS ANNOUNCES PRIMARY ENDPOINT MET IN PHASE 2 STUDY IN PANCREATIC CANCER
August 4, 2021
ACTUATE THERAPEUTICS ANNOUNCES FDA FAST TRACK DESIGNATION FOR 9-ING-41 FOR TREATMENT OF PANCREATIC CANCER
July 31, 2020
ACTUATE THERAPEUTICS ANNOUNCES INITIATION OF PHASE 2 CLINICAL STUDY IN PANCREATIC CANCER
PARTNERING
As we continue to develop novel therapies to improve outcomes for patients. We are open to new partnerships with academic and scientific organizations.